Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS
Santiago Osorio(Institut Català d'Oncologia), Juan Luis Steegmann(Hospital Universitario de La Princesa), M. Andrade(Hospital Universitario Miguel Servet), Pilar Giraldo(Université Paris-Saclay), Rosa Ayala(Hospital Universitario 12 De Octubre), Beatriz Maestro(Universitat de Miguel Hernández d'Elx), Nailde Gabriela Cantanhede Garcia(Hospital Virgen de la Salud), Valentín García‐Gutiérrez(Universidad de Alcalá), Luis Casado(Hospital Universitario de La Princesa), Sara Redondo(Hospital de Sant Pau)
Cited by 9
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
|Leukemia|2016|473
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464